VivoSense, Inc.

VivoSense, Inc. is a pioneering company in the field of data analysis consulting and software, focusing on wearable sensor physiological monitoring solutions for clinical trials, healthcare research, and consumer wellness. Established in 2010 and headquartered in the United States, VivoSense has made significant strides in the development of regulatory compliant digital biomarkers utilizing data from wearable sensors. These digital biomarkers play a crucial role in accurately measuring drug and treatment effects in regulated clinical trials and healthcare research. What sets VivoSense apart is its distinction as the first analytics company to devise novel digital biomarkers from wearable sensor data, which are integral in regulated international pharmaceutical trials as primary and secondary clinical endpoints. Notably, the company has managed to advance numerous studies in rare disease indications, reaching the open-label phase of development at top-ten pharma. The most recent grant investment received by VivoSense, Inc. was on 19 January 2023, facilitated by MassAITC and the National Institute on Aging. This further underscores the company's potential and the significance of its contributions to the healthcare and biotechnology industries.